Targeting ERβ/TGFβ1/SMAD3 signals with selective estrogen receptor modulators (e.g. a FDA‐approved anti‐estrogen, Faslodex, or an ERβ selective antagonist, PHTPP) could help in the development of new therapies to better treat RCC patients. This evidence concerns the gene ESR1 and renal cell carcinoma.